Cancer Vaccine Final IQP

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.

  2015cited by this paper
• Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

  2015cited by this paper
• Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

  2014cited by this paper
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

  2014cited by this paper
• From the Mouse Cage to Human Therapy: A Personal Perspective of the Emergence of T-bodies/Chimeric Antigen Receptor T Cells

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  2014cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

  2014cited by this paper
• Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

  2013cited by this paper
• Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper
• Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical Trials

  2013cited by this paper
• Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• The dizzying journey to a new cancer arsenal.

  2013cited by this paper
• IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity.

  2013cited by this paper
• Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

  2013cited by this paper
• Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

  2013cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

  2013cited by this paper
• Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.

  2013cited by this paper
• Digital Genomic Quantification of Tumor-Infiltrating Lymphocytes

  2013cited by this paper
• Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• Prostate cancer treatment unblinded.

  2012cited by this paper
• Glioblastoma survival in the United States before and during the temozolomide era

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions

  2012cited by this paper
• The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer

  2012cited by this paper
• Targeting the subtypes of breast cancer: rethinking investigational drugs

  2012cited by this paper
• Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

  2012cited by this paper
• Redirecting T cells.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

  2011cited by this paper
• Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011influential reference
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011cited by this paper
• 樹状細胞 (dendritic cell)

  2011cited by this paper
• Regulatory T Cells

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Ultraviolet radiation and melanoma.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Harnessing human dendritic cell subsets for medicine

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• European Organization for Research and Treatment of Cancer

  2010cited by this paper
• Preclinical development of T cell receptor gene therapy.

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009influential reference
• CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues

  2008cited by this paper
• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

  2008cited by this paper
• Cancer vaccines for established cancer: how to make them better?

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

  2008cited by this paper
• Reengineering dendritic cell‐based anti‐cancer vaccines

  2008cited by this paper
• CD8+ T cell efficacy in vaccination and disease

  2008cited by this paper
• Twelve immunotherapy drugs that could cure cancers.

  2008cited by this paper
• Functions of natural killer cells

  2008cited by this paper
• Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials1

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.

  2007cited by this paper
• Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

  2007cited by this paper
• Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell Immunity

  2006cited by this paper
• Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

  2006cited by this paper
• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  2006influential reference
• Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• Prevalent mutations in prostate cancer

  2006cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

  2005cited by this paper
• Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity

  2005cited by this paper
• Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

  2005cited by this paper
• Dendritic-cell-based therapeutic vaccination against cancer.

  2005cited by this paper
• Genetic Analysis of the RNASEL Gene in Hereditary, Familial, and Sporadic Prostate Cancer

  2004influential reference
• Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture — No correlation with the postsurgical clinical course

  2004cited by this paper
• Rational approaches to human cancer immunotherapy

  2003cited by this paper
• Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

  2003cited by this paper
• Single Injection of CD34+ Progenitor-Derived Dendritic Cell Vaccine Can Lead to Induction of T-Cell Immunity in Patients With Stage IV Melanoma

  2003cited by this paper
• Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.

  2003cited by this paper
• Metastatic melanoma: chemotherapy.

  2002cited by this paper
• Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody

  2002cited by this paper
• Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial.

  2002cited by this paper

• No citing papers are available for this paper.